This Article Full Text Full Text (PDF) All Versions of this Article: 148/1/4    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ostrowski, J. Articles by Hamann, L. G. Search for Related Content PubMed PubMed Citation Articles by Ostrowski, J. Articles by Hamann, L. G.

Pharmacological and X-Ray Structural Characterization of a Novel Selective Androgen Receptor Modulator: Potent Hyperanabolic Stimulation of Skeletal Muscle with Hypostimulation of Prostate in Rats

Departments of Metabolic Diseases (J.O., J.E.K., J.A.L., B.C.B., R.S., R.G., P.G.S., K.A.M., G.J.G.), Discovery Chemistry (M.C.M., Y.B., C.S., L.G.H.), Macromolecular Structure (S.R.K., Y.A., K.F.K., J.S.S.), and Pharmaceutical Candidate Optimization (A.F.), Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543

Address all correspondence and requests for reprints to: Lawrence G. Hamann: Department of Discovery Chemistry, Bristol-Myers Squibb, Pharmaceutical Research Institute, 5 Research Parkway, Wallingford Connecticut 06492. E-mail: lawrence.hamann{at}bms.com.

A novel, highly potent, orally active, nonsteroidal tissue selective androgen receptor (AR) modulator (BMS-564929) has been identified, and this compound has been advanced to clinical trials for the treatment of age-related functional decline. BMS-564929 is a subnanomolar AR agonist in vitro, is highly selective for the AR vs. other steroid hormone receptors, and exhibits no significant interactions with SHBG or aromatase. Dose response studies in castrated male rats show that BMS-564929 is substantially more potent than testosterone (T) in stimulating the growth of the levator ani muscle, and unlike T, highly selective for muscle vs. prostate. Key differences in the binding interactions of BMS-564929 with the AR relative to the native hormones were revealed through x-ray crystallography, including several unique contacts located in specific helices of the ligand binding domain important for coregulatory protein recruitment. Results from additional pharmacological studies effectively exclude alternative mechanistic contributions to the observed tissue selectivity of this unique, orally active androgen. Because concerns regarding the potential hyperstimulatory effects on prostate and an inconvenient route of administration are major drawbacks that limit the clinical use of T, the potent oral activity and tissue selectivity exhibited by BMS-564929 are expected to yield a clinical profile that provides the demonstrated beneficial effects of T in muscle and other tissues with a more favorable safety window.

This article has been cited by other articles:

				S. T. Page, B. T. Marck, J. M. Tolliver, and A. M. Matsumoto Tissue Selectivity of the Anabolic Steroid, 19-Nor-4-Androstenediol-3{beta},17{beta}-Diol in Male Sprague Dawley Rats: Selective Stimulation of Muscle Mass and Bone Mineral Density Relative to Prostate Mass Endocrinology, April 1, 2008; 149(4): 1987 - 1993. [Abstract] [Full Text] [PDF]

				J. Chen, K. C. Ahn, N. A. Gee, M. I. Ahmed, A. J. Duleba, L. Zhao, S. J. Gee, B. D. Hammock, and B. L. Lasley Triclocarban Enhances Testosterone Action: A New Type of Endocrine Disruptor? Endocrinology, March 1, 2008; 149(3): 1173 - 1179. [Abstract] [Full Text] [PDF]

				E. B. Askew, R. T. Gampe Jr., T. B. Stanley, J. L. Faggart, and E. M. Wilson Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone J. Biol. Chem., August 31, 2007; 282(35): 25801 - 25816. [Abstract] [Full Text] [PDF]

				N. Sharifi, E. Hamel, M. A. Lill, P. Risbood, C. T. Kane Jr., M. T. Hossain, A. Jones, J. T. Dalton, and W. L. Farrar A bifunctional colchicinoid that binds to the androgen receptor Mol. Cancer Ther., August 1, 2007; 6(8): 2328 - 2336. [Abstract] [Full Text] [PDF]

				W. Gao and J. T. Dalton Ockham's Razor and Selective Androgen Receptor Modulators (SARMs): Are We Overlooking the Role of 5{alpha}-Reductase? Mol. Interv., February 1, 2007; 7(1): 10 - 13. [Abstract] [Full Text] [PDF]

				E. M. Wilson Muscle-Bound? A Tissue-Selective Nonsteroidal Androgen Receptor Modulator Endocrinology, January 1, 2007; 148(1): 1 - 3. [Full Text] [PDF]